Jeroen Van Den Oever

DOPPL SA is a spin out of SUN bioscience SA and a leader in engineering industry-standard organoids for disease modeling and personalized medicine. We engage in partnered projects for preclinical drug development by providing relevant, high-quality, and scalable organoid models.

The microbiome is the ecosystem of micro-organisms that live in and around us, mostly in our gut. It plays a major role in human health, and when out of balance causes diseases such as chronic digestive disorders, diabetes, obesity, allergies, auto-immune diseases and much else. We have a genotype and a phenotype. What everyone also has is a "microtype:"​ The composition of the microbiome. It affects the response to treatments as well as our food and lifestyle. REM Analytics provides a novel method to profile the microtype in people. For companies producing probiotics, prebiotics, functional foods or other microbiome affecting products, we provide the evidence needed to demonstrate the efficacy of your products. We have the unique capability to measure the colonization of specific probiotic strain in the microbiome of people. Also, we can measure the effect of these strains on the microtype at large, as well as differences induced by changes in food and lifestyle. Accurate profiling of the microtype has the potential to identify sub-populations that are more likely to be treated by a probiotic. In the long run, our objecitve is to allow the development of Evidence-based, personalised microbiome based treatments.

SUN bioscience is enabling personalized medicine through its SUN’s proprietary high-throughput 3D microwell platform. Organoids are self-organizing 3D miniature tissues with organ-mimicking functions that are grown from stem cells. They are powerful human in vitro models for assessing pharmaceutical efficacy and toxicity early on in drug development. Our flagship technology Gri3D® is solving the challenges of organoid culture: automation, robustness, scalability, and easy imaging. This will introduce a new era in drug development.

DOPPL SA is a spin out of SUN bioscience SA and a leader in engineering industry-standard organoids for disease modeling and personalized medicine. We engage in partnered projects for preclinical drug development by providing relevant, high-quality, and scalable organoid models.

Together with successful founders, key academic and industry partners; Venturelab designs and operates programs to bring the best #startup talents to the next level of development. Our mission is to support entrepreneurs towards successful fundraising and business growth throughout the evolution of the company. With Venture Leaders, we take the Swiss National Startup Teams to Silicon Valley, San Francisco, Boston, New York, London, Munich, Barcelona, and China, supporting them on their global expansion path. We are also proud of the success of our mandate to run the operations of Venture Kick since its launch in 2007, having kicked off 1,121 Swiss startup projects with CHF 80 million from private donors. Thanks to financial support, coaching, and networking with investors, this initiative has led to the emergence of 750 thriving startups and the creation of 14,500 jobs. Venture Kick alumni companies have attracted investments of CHF 9 billion and represent 66 companies ranked in the TOP 100 Swiss Startups in 2024. Our team operates from our startup space in Zurich and offices in Lausanne and St Gallen.

The microbiome is the ecosystem of micro-organisms that live in and around us, mostly in our gut. It plays a major role in human health, and when out of balance causes diseases such as chronic digestive disorders, diabetes, obesity, allergies, auto-immune diseases and much else. We have a genotype and a phenotype. What everyone also has is a "microtype:"​ The composition of the microbiome. It affects the response to treatments as well as our food and lifestyle. REM Analytics provides a novel method to profile the microtype in people. For companies producing probiotics, prebiotics, functional foods or other microbiome affecting products, we provide the evidence needed to demonstrate the efficacy of your products. We have the unique capability to measure the colonization of specific probiotic strain in the microbiome of people. Also, we can measure the effect of these strains on the microtype at large, as well as differences induced by changes in food and lifestyle. Accurate profiling of the microtype has the potential to identify sub-populations that are more likely to be treated by a probiotic. In the long run, our objecitve is to allow the development of Evidence-based, personalised microbiome based treatments.

SUN bioscience is enabling personalized medicine through its SUN’s proprietary high-throughput 3D microwell platform. Organoids are self-organizing 3D miniature tissues with organ-mimicking functions that are grown from stem cells. They are powerful human in vitro models for assessing pharmaceutical efficacy and toxicity early on in drug development. Our flagship technology Gri3D® is solving the challenges of organoid culture: automation, robustness, scalability, and easy imaging. This will introduce a new era in drug development.